{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:55:19Z","timestamp":1759146919654,"version":"3.40.3"},"reference-count":179,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780323990264"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/bs.irn.2023.06.002","type":"book-chapter","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T05:02:05Z","timestamp":1688533325000},"page":"217-258","source":"Crossref","is-referenced-by-count":2,"title":["Advances in targeting neurotransmitter systems in dystonia"],"prefix":"10.1016","author":[{"given":"Dora","family":"Steel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberley M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen J.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manju A.","family":"Kurian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/bs.irn.2023.06.002_bib1","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00424-020-02420-2","article-title":"Neuronal alpha2delta proteins and brain disorders","volume":"472","author":"Ablinger","year":"2020","journal-title":"Pflugers Archiv: European Journal of Physiology"},{"issue":"7","key":"10.1016\/bs.irn.2023.06.002_bib2","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.25475","article-title":"Phenomenology and classification of dystonia: A consensus update","volume":"28","author":"Albanese","year":"2013","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"4","key":"10.1016\/bs.irn.2023.06.002_bib3","first-page":"230","article-title":"Dopaminergic agonists in Parkinson\u2019s disease","volume":"29","author":"Alonso Canovas","year":"2014","journal-title":"Neurologia (Barcelona, Spain)"},{"key":"10.1016\/bs.irn.2023.06.002_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174178","article-title":"siRNA: Mechanism of action, challenges, and therapeutic approaches","volume":"905","author":"Alshaer","year":"2021","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2023.06.002_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108719","article-title":"Glutamate metabolism and recycling at the excitatory synapse in health and neurodegeneration","volume":"196","author":"Andersen","year":"2021","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2023.06.002_bib6","first-page":"1","article-title":"Epilepsy and cannabidiol: A guide to treatment","volume":"22","author":"Arzimanoglou","year":"2020","journal-title":"Epileptic Disorders: International Epilepsy Journal with Videotape"},{"issue":"12","key":"10.1016\/bs.irn.2023.06.002_bib7","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","article-title":"The epidemiology of Parkinson\u2019s disease: Risk factors and prevention","volume":"15","author":"Ascherio","year":"2016","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2023.06.002_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3233\/JPD-181331","article-title":"Gene therapy for Parkinson\u2019s disease, An update","volume":"8","author":"Axelsen","year":"2018","journal-title":"Journal of Parkinson\u2019s Disease"},{"key":"10.1016\/bs.irn.2023.06.002_bib9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fneur.2019.00218","article-title":"Parkinson\u2019s disease and the environment","volume":"10","author":"Ball","year":"2019","journal-title":"Frontiers in Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2023.06.002_bib10","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1152\/physrev.00017.2006","article-title":"GABA: A pioneer transmitter that excites immature neurons and generates primitive oscillations","volume":"87","author":"Ben-Ari","year":"2007","journal-title":"Physiological Reviews"},{"issue":"8","key":"10.1016\/bs.irn.2023.06.002_bib11","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/mds.25920","article-title":"The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model","volume":"29","author":"Bezard","year":"2014","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"6","key":"10.1016\/bs.irn.2023.06.002_bib12","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00424-021-02580-9","article-title":"One hundred years from Otto Loewi experiment, a dream that revolutionized our view of neurotransmission","volume":"473","author":"Borges","year":"2021","journal-title":"Pflugers Archiv: European Journal of Physiology"},{"issue":"23","key":"10.1016\/bs.irn.2023.06.002_bib13","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1021\/acschemneuro.1c00175","article-title":"Spontaneous adenosine and dopamine cotransmission in the caudate-putamen is regulated by adenosine receptors","volume":"12","author":"Borgus","year":"2021","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/bs.irn.2023.06.002_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fncir.2021.638007","article-title":"Locus coeruleus norepinephrine in learned behavior: Anatomical modularity and spatiotemporal integration in targets","volume":"15","author":"Breton-Provencher","year":"2021","journal-title":"Front Neural Circuits"},{"issue":"3","key":"10.1016\/bs.irn.2023.06.002_bib15","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/brain\/awab423","article-title":"Antisense therapies in neurological diseases","volume":"145","author":"Brunet de Courssou","year":"2022","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2023.06.002_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104579","article-title":"Dystonia and levodopa-induced dyskinesias in Parkinson\u2019s disease: Is there a connection?","volume":"132","author":"Calabresi","year":"2019","journal-title":"Neurobiology of Disease"},{"issue":"6","key":"10.1016\/bs.irn.2023.06.002_bib17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/00000441-194921860-00007","article-title":"Clinical experiences in parkinsonism with a new type of antispasmodic, 3-(piperidyl)-1-phenyl-1-cyclohexyl-1-propanol hydrochloride (artane)","volume":"218","author":"Canelis","year":"1949","journal-title":"The American Journal of the Medical Sciences"},{"issue":"4596","key":"10.1016\/bs.irn.2023.06.002_bib18","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/1801200a0","article-title":"3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists","volume":"180","author":"Carlsson","year":"1957","journal-title":"Nature"},{"key":"10.1016\/bs.irn.2023.06.002_bib19","first-page":"CD006661","article-title":"Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson\u2019s disease","volume":"4","author":"Caslake","year":"2009","journal-title":"Cochrane Database of Systematic Reviews (Online)"},{"issue":"6","key":"10.1016\/bs.irn.2023.06.002_bib20","first-page":"697","article-title":"Monoamine oxidase A and B substrates: Probing the pathway for drug development","volume":"6","author":"Chajkowski-Scarry","year":"2014","journal-title":"Future\u00a0Medicinal Chemistry"},{"key":"10.1016\/bs.irn.2023.06.002_bib21","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.neuroscience.2019.04.008","article-title":"Effects of muscarinic acetylcholine m1 and m4 receptor blockade on dyskinesia in the hemi-parkinsonian rat","volume":"409","author":"Chambers","year":"2019","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/bs.irn.2023.06.002_bib22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ana.20055","article-title":"Levodopa-responsive aromatic L-amino acid decarboxylase deficiency","volume":"55","author":"Chang","year":"2004","journal-title":"Annals of Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2023.06.002_bib23","article-title":"MicroRNA profile differences in neonates at risk for cerebral palsy","volume":"5","author":"Chapman","year":"2018","journal-title":"Physical Medicine and Rehabilitation International"},{"issue":"5","key":"10.1016\/bs.irn.2023.06.002_bib24","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/brain\/awaa085","article-title":"Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy","volume":"143","author":"Chatron","year":"2020","journal-title":"Brain"},{"issue":"3","key":"10.1016\/bs.irn.2023.06.002_bib25","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1476-5381.1988.tb11719.x","article-title":"Agonists at mu-opioid, M2-muscarinic and GABAB-receptors increase the same potassium conductance in rat lateral parabrachial neurones","volume":"95","author":"Christie","year":"1988","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2023.06.002_bib26","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1212\/WNL.0000000000012952","article-title":"Safety of AADC gene therapy for moderately advanced Parkinson disease: Three-year outcomes from the PD-1101 trial","volume":"98","author":"Christine","year":"2022","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/bs.irn.2023.06.002_bib27","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/brain\/awaa181","article-title":"Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa","volume":"143","author":"Cilia","year":"2020","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2023.06.002_bib28","unstructured":"ClinicalTrials.gov. (2020). Study in Parkinson\u2019s disease patients with dyskinesia with combinations of JM-010 and its individual components (SHINE). Retrieved 08\/07\/2022, from \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04377945\u3009."},{"key":"10.1016\/bs.irn.2023.06.002_bib29","unstructured":"ClinicalTrials.gov. (2021). AV-101 (L-4-chlorokynurenine) in Parkinson\u2019s disease subjects with levodopa-induced dyskinesia. ClinicalTrials.gov. Retrieved 08\/07\/2022, from \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04147949\u3009."},{"issue":"16","key":"10.1016\/bs.irn.2023.06.002_bib30","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: A review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA: The Journal of the American Medical Association"},{"issue":"7","key":"10.1016\/bs.irn.2023.06.002_bib31","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.nrl.2017.08.009","article-title":"New transgenic models of Parkinson\u2019s disease using genome editing technology","volume":"35","author":"Cota-Coronado","year":"2020","journal-title":"Neurologia (Engl Ed)"},{"issue":"1","key":"10.1016\/bs.irn.2023.06.002_bib32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40478-020-0878-0","article-title":"Thalamostriatal degeneration contributes to dystonia and cholinergic interneuron dysfunction in a mouse model of Huntington's disease","volume":"8","author":"Crevier-Sorbo","year":"2020","journal-title":"Acta Neuropathologica Communications"},{"issue":"1","key":"10.1016\/bs.irn.2023.06.002_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","article-title":"Cannabinoids and the expanded endocannabinoid system in neurological disorders","volume":"16","author":"Cristino","year":"2020","journal-title":"Nature Reviews Neurology"},{"issue":"12","key":"10.1016\/bs.irn.2023.06.002_bib34","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1007\/s11064-008-9694-9","article-title":"Metabotropic glutamate receptors in glial cells","volume":"33","author":"D'Antoni","year":"2008","journal-title":"Neurochemical Research"},{"issue":"11","key":"10.1016\/bs.irn.2023.06.002_bib35","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.cub.2015.04.022","article-title":"Acetylcholine mediates behavioral and neural post-error control","volume":"25","author":"Danielmeier","year":"2015","journal-title":"Current Biology: CB"},{"issue":"5","key":"10.1016\/bs.irn.2023.06.002_bib36","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1212\/WNL.0b013e3182452849","article-title":"Child Neurology: Paroxysmal stiffening, upward gaze, and hypotoniaHallmarks of sepiapterin reductase deficiency","volume":"78","author":"Dill","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2023.06.002_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105699","article-title":"Blockade of M4 muscarinic receptors on striatal cholinergic interneurons normalizes striatal dopamine release in a mouse model of TOR1A dystonia","volume":"168","author":"Downs","year":"2022","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/bs.irn.2023.06.002_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104526","article-title":"The neurobiological basis for novel experimental therapeutics in dystonia","volume":"130","author":"Downs","year":"2019","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/bs.irn.2023.06.002_bib39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.neuroscience.2018.11.010","article-title":"Diversity and specificity of astrocyte-neuron communication","volume":"396","author":"Durkee","year":"2019","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/bs.irn.2023.06.002_bib40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jamda.2020.04.019","article-title":"Anticholinergic drug burden and delirium: A systematic review","volume":"22","author":"Egberts","year":"2021","journal-title":"Journal of the American Medical Directors Association"},{"issue":"1","key":"10.1016\/bs.irn.2023.06.002_bib41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/EJE-12-0121","article-title":"Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment","volume":"167","author":"Elenkova","year":"2012","journal-title":"European Journal of Endocrinology\/European Federation of Endocrine Societies"},{"issue":"3","key":"10.1016\/bs.irn.2023.06.002_bib42","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.cell.2020.09.022","article-title":"Endocannabinoids inhibit the induction of virulence in enteric pathogens","volume":"183","author":"Ellermann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/bs.irn.2023.06.002_bib43","unstructured":"EMA. (2021). Refusal of the marketing authorisation for Nouryant (istradefylline). E. M. Agency."},{"key":"10.1016\/bs.irn.2023.06.002_bib44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pneurobio.2015.02.002","article-title":"Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystonia","volume":"127\u2013128","author":"Eskow Jaunarajs","year":"2015","journal-title":"Progress in Neurobiology"},{"issue":"9","key":"10.1016\/bs.irn.2023.06.002_bib45","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/dmcn.14548","article-title":"Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: A randomized controlled trial","volume":"62","author":"Fairhurst","year":"2020","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2023.06.002_bib46","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1136\/jnnp-2013-305532","article-title":"The treatment of dystonic tremor: A systematic review","volume":"85","author":"Fasano","year":"2014","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"22","key":"10.1016\/bs.irn.2023.06.002_bib47","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1016\/j.cell.2021.10.009","article-title":"GABA-receptive microglia selectively sculpt developing inhibitory circuits","volume":"184","author":"Favuzzi","year":"2021","journal-title":"Cell"},{"issue":"4","key":"10.1016\/bs.irn.2023.06.002_bib48","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1113\/jphysiol.1945.sp004085","article-title":"Synthesis of acetylcholine by tissue of the central nervous system","volume":"103","author":"Feldberg","year":"1945","journal-title":"The Journal of Physiology"},{"issue":"Pt C","key":"10.1016\/bs.irn.2023.06.002_bib49","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.neuropharm.2018.01.028","article-title":"Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases","volume":"136","author":"Felder","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.irn.2023.06.002_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109329","article-title":"Presynaptic adenosine receptor heteromers as key modulators of glutamatergic and dopaminergic neurotransmission in the striatum","volume":"223","author":"Ferre","year":"2023","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/bs.irn.2023.06.002_bib51","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/mds.28495","article-title":"An update on the phenotype, genotype and neurobiology of ADCY5-related disease","volume":"36","author":"Ferrini","year":"2021","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"1","key":"10.1016\/bs.irn.2023.06.002_bib52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/mds.1280","article-title":"Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia","volume":"17","author":"Fox","year":"2002","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"5","key":"10.1016\/bs.irn.2023.06.002_bib53","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/mdc3.13229","article-title":"An open-label phase 2a study to evaluate the safety and tolerability of perampanel in cervical dystonia","volume":"8","author":"Fox","year":"2021","journal-title":"Movement Disorders Clinical Practice"},{"issue":"8","key":"10.1016\/bs.irn.2023.06.002_bib54","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1007\/s00018-021-03761-6","article-title":"Structure and function of adenosine receptor heteromers","volume":"78","author":"Franco","year":"2021","journal-title":"Cellular and Molecular Life Sciences: CMLS"},{"issue":"1","key":"10.1016\/bs.irn.2023.06.002_bib55","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41598-020-80211-6","article-title":"The effects of anticholinergic medications on cognition in children: A systematic review and meta-analysis","volume":"11","author":"Ghezzi","year":"2021","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.irn.2023.06.002_bib56","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.parkreldis.2021.09.024","article-title":"ND0612 (levodopa\/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study","volume":"91","author":"Giladi","year":"2021","journal-title":"Parkinsonism & Related Disorders"},{"issue":"22","key":"10.1016\/bs.irn.2023.06.002_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20225649","article-title":"Role of MicroRNAs in Parkinson's disease","volume":"20","author":"Goh","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.irn.2023.06.002_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128637","article-title":"Rationalizing the binding and alpha subtype selectivity of synthesized imidazodiazepines and benzodiazepines at GABAA receptors by using molecular docking studies","volume":"62","author":"Golani","year":"2022","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/bs.irn.2023.06.002_bib59","doi-asserted-by":"crossref","first-page":"15082","DOI":"10.1038\/nrdp.2015.82","article-title":"Cerebral palsy","volume":"2","author":"Graham","year":"2016","journal-title":"Nature Reviews Disease Primers"},{"issue":"17","key":"10.1016\/bs.irn.2023.06.002_bib60","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1093\/hmg\/ddaa179","article-title":"Gene therapy for Alzheimer's disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation","volume":"29","author":"Griciuc","year":"2020","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/bs.irn.2023.06.002_bib61","unstructured":"GTEx. (2015). The genotype tissue expression project. GTEx Consortium, National Institute of Health."},{"issue":"1","key":"10.1016\/bs.irn.2023.06.002_bib62","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000129","article-title":"A gain-of-function mutation in the GRIK2 gene causes neurodevelopmental deficits","volume":"3","author":"Guzman","year":"2017","journal-title":"Neurology Genetics"},{"issue":"8","key":"10.1016\/bs.irn.2023.06.002_bib63","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/mt.2010.106","article-title":"Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC","volume":"18","author":"Hadaczek","year":"2010","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"issue":"14","key":"10.1016\/bs.irn.2023.06.002_bib64","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/0006-2952(72)90013-5","article-title":"Amantadine and catecholamine uptake","volume":"21","author":"Herblin","year":"1972","journal-title":"Biochemical Pharmacology"},{"issue":"8","key":"10.1016\/bs.irn.2023.06.002_bib65","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1093\/brain\/awx177","article-title":"Encephalitis lethargica: 100 years after the epidemic","volume":"140","author":"Hoffman","year":"2017","journal-title":"Brain"},{"issue":"6","key":"10.1016\/bs.irn.2023.06.002_bib66","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/0883073818756134","article-title":"GNAO1 mutation-induced pediatric dystonic storm rescue with pallidal deep brain stimulation","volume":"33","author":"Honey","year":"2018","journal-title":"Journal of Child Neurology"},{"issue":"134","key":"10.1016\/bs.irn.2023.06.002_bib67","doi-asserted-by":"crossref","first-page":"134ra161","DOI":"10.1126\/scitranslmed.3003640","article-title":"Gene therapy for aromatic L-amino acid decarboxylase deficiency","volume":"4","author":"Hwu","year":"2012","journal-title":"Science Translational Medicine"},{"issue":"4","key":"10.1016\/bs.irn.2023.06.002_bib68","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/(SICI)1098-2396(199712)27:4<357::AID-SYN9>3.0.CO;2-B","article-title":"Differential expression of D1 and D2 dopamine and m4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons","volume":"27","author":"Ince","year":"1997","journal-title":"Synapse (New York, N. Y.)"},{"issue":"3","key":"10.1016\/bs.irn.2023.06.002_bib69","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1620\/tjem.154.233","article-title":"Effect of tetrahydrobiopterin and 5-hydroxytryptophan on hereditary progressive dystonia with marked diurnal fluctuation: a suggestion of the serotonergic system involvement","volume":"154","author":"Ishida","year":"1988","journal-title":"Tohoku J Exp Med"},{"issue":"7","key":"10.1016\/bs.irn.2023.06.002_bib70","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.ajhg.2022.05.009","article-title":"Identification and functional evaluation of GRIA1 missense and truncation variants in individuals with ID: An emerging neurodevelopmental syndrome","volume":"109","author":"Ismail","year":"2022","journal-title":"American Journal of Human Genetics"},{"issue":"3","key":"10.1016\/bs.irn.2023.06.002_bib71","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/14737175.2021.1880896","article-title":"Istradefylline\u2014A first generation adenosine A2A antagonist for the treatment of Parkinson's disease","volume":"21","author":"Jenner","year":"2021","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"1","key":"10.1016\/bs.irn.2023.06.002_bib72","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41386-019-0444-2","article-title":"Arousal and sleep circuits","volume":"45","author":"Jones","year":"2020","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/bs.irn.2023.06.002_bib73","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1176\/appi.ajp.2020.20081212","article-title":"Anticholinergic medication burden-associated cognitive impairment in schizophrenia","volume":"178","author":"Joshi","year":"2021","journal-title":"The American Journal of Psychiatry"},{"issue":"7","key":"10.1016\/bs.irn.2023.06.002_bib74","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/01.wnl.0000310812.43352.66","article-title":"Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD","volume":"71","author":"Katzenschlager","year":"2008","journal-title":"Neurology"},{"issue":"20","key":"10.1016\/bs.irn.2023.06.002_bib75","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1212\/WNL.0000000000003936","article-title":"Phenotype of GABA-transaminase deficiency","volume":"88","author":"Koenig","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2023.06.002_bib76","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/brain\/awy331","article-title":"Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency","volume":"142","author":"Kojima","year":"2019","journal-title":"Brain"},{"issue":"4","key":"10.1016\/bs.irn.2023.06.002_bib77","article-title":"Artificial miRNAs as therapeutic tools: Challenges and opportunities","volume":"12","author":"Kotowska-Zimmer","year":"2021","journal-title":"Wiley Interdisciplinary Reviews: RNA"},{"issue":"1","key":"10.1016\/bs.irn.2023.06.002_bib78","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.nbd.2004.01.012","article-title":"Increased excitability in cortico-striatal synaptic pathway in a model of paroxysmal dystonia","volume":"16","author":"K\u00f6hling","year":"2004","journal-title":"Neurobiol Dis"},{"issue":"7306","key":"10.1016\/bs.irn.2023.06.002_bib79","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nature09159","article-title":"Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry","volume":"466","author":"Kravitz","year":"2010","journal-title":"Nature"},{"issue":"6","key":"10.1016\/bs.irn.2023.06.002_bib80","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.ejpn.2016.07.021","article-title":"Effective treatment of spasticity using dronabinol in pediatric palliative care","volume":"20","author":"Kuhlen","year":"2016","journal-title":"European Journal of Paediatric Neurology: EJPN: Official Journal of the European Paediatric Neurology Society"},{"issue":"6","key":"10.1016\/bs.irn.2023.06.002_bib81","first-page":"1595","article-title":"Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia","volume":"119","author":"Kurian","year":"2009","journal-title":"The Journal of Clinical Investigation"},{"issue":"2","key":"10.1016\/bs.irn.2023.06.002_bib82","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.nec.2018.12.002","article-title":"Intrathecal baclofen infusion for the treatment of movement disorders","volume":"30","author":"Lake","year":"2019","journal-title":"Neurosurgery Clinics of North America"},{"issue":"2","key":"10.1016\/bs.irn.2023.06.002_bib83","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/BF02244197","article-title":"Selectivity of antimuscarinic compounds for muscarinic receptors of human brain and heart","volume":"103","author":"Larson","year":"1991","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/bs.irn.2023.06.002_bib84","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ng.2726","article-title":"GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction","volume":"45","author":"Lesca","year":"2013","journal-title":"Nature Genetics"},{"issue":"3","key":"10.1016\/bs.irn.2023.06.002_bib85","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1755-5949.2010.00142.x","article-title":"Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders","volume":"16","author":"Lester","year":"2010","journal-title":"CNS Neuroscience & Therapeutics"},{"key":"10.1016\/bs.irn.2023.06.002_bib86","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.parkreldis.2019.05.032","article-title":"Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill(R)) in Parkinson\u2019s disease","volume":"65","author":"LeWitt","year":"2019","journal-title":"Parkinsonism & Related Disorders"},{"issue":"4","key":"10.1016\/bs.irn.2023.06.002_bib87","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ajhg.2016.07.013","article-title":"GRIN2D recurrent de novo dominant mutation causes a severe epileptic encephalopathy treatable with NMDA receptor channel blockers","volume":"99","author":"Li","year":"2016","journal-title":"American Journal of Human Genetics"},{"issue":"9","key":"10.1016\/bs.irn.2023.06.002_bib88","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0883073818773028","article-title":"Medical cannabis for pediatric moderate to severe complex motor disorders","volume":"33","author":"Libzon","year":"2018","journal-title":"Journal of Child Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2023.06.002_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19072143","article-title":"A history of the pharmacological treatment of bipolar disorder","volume":"19","author":"Lopez-Munoz","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"issue":"7","key":"10.1016\/bs.irn.2023.06.002_bib90","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","article-title":"A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease","volume":"263","author":"Lopez-Sendon Moreno","year":"2016","journal-title":"Journal of Neurology"},{"issue":"8","key":"10.1016\/bs.irn.2023.06.002_bib91","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/archdischild-2018-316309","article-title":"Pharmacological management of abnormal tone and movement in cerebral palsy","volume":"104","author":"Lumsden","year":"2019","journal-title":"Archives of Disease in Childhood"},{"key":"10.1016\/bs.irn.2023.06.002_bib92","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3389\/fphar.2019.01488","article-title":"Striatal cholinergic interneurons: How to elucidate their function in health and disease","volume":"10","author":"Mallet","year":"2019","journal-title":"Frontiers in Pharmacology"},{"issue":"13","key":"10.1016\/bs.irn.2023.06.002_bib93","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/mds.26009","article-title":"Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: Role of M1 muscarinic receptors","volume":"29","author":"Maltese","year":"2014","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"key":"10.1016\/bs.irn.2023.06.002_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108608","article-title":"Rescue of striatal long-term depression by chronic mGlu5 receptor negative allosteric modulation in distinct dystonia models","volume":"192","author":"Martella","year":"2021","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/bs.irn.2023.06.002_bib95","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ajhg.2017.11.004","article-title":"De novo variants in GRIA4 lead to intellectual disability with or without seizures and gait abnormalities","volume":"101","author":"Martin","year":"2017","journal-title":"American Journal of Human Genetics"},{"key":"10.1016\/bs.irn.2023.06.002_bib96","article-title":"Cannabidiol acts at 5-HT1A receptors in the human brain: Relevance for treating temporal lobe epilepsy","volume":"14","author":"Martinez-Aguirre","year":"2020","journal-title":"Frontiers in Behavioral Neuroscienc"},{"key":"10.1016\/bs.irn.2023.06.002_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2021.630600","article-title":"Genome editing in iPSC-based neural systems: From disease models to future therapeutic strategies","volume":"3","author":"McTague","year":"2021","journal-title":"Frontiers in Genome Editing"},{"issue":"6","key":"10.1016\/bs.irn.2023.06.002_bib98","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/mds.29006","article-title":"Efficacy of caffeine in ADCY5-related dyskinesia: A retrospective study","volume":"37","author":"Meneret","year":"2022","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"4","key":"10.1016\/bs.irn.2023.06.002_bib99","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/mdc3.13448","article-title":"Diagnostic neurophysiologic biomarkers for task-specific dystonia","volume":"9","author":"Merchant","year":"2022","journal-title":"Movement Disorders Clinical Practice"},{"key":"10.1016\/bs.irn.2023.06.002_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.648532","article-title":"Gene therapy in movement disorders: A systematic review of ongoing and completed clinical trials","volume":"12","author":"Merola","year":"2021","journal-title":"Frontiers in Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2023.06.002_bib101","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ng.3740","article-title":"Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia","volume":"49","author":"Meyer","year":"2017","journal-title":"Nature Genetics"},{"key":"10.1016\/bs.irn.2023.06.002_bib102","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.parkreldis.2016.08.005","article-title":"Caffeine consumption and the 4-year progression of de novo Parkinson's disease","volume":"32","author":"Moccia","year":"2016","journal-title":"Parkinsonism & Related Disorders"},{"issue":"2","key":"10.1016\/bs.irn.2023.06.002_bib103","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0304-3940(86)90080-7","article-title":"Activation of M2 muscarinic receptors causes an alteration of action potentials by modulation of Ca entry in isolated sympathetic neurons of rabbits","volume":"72","author":"Mochida","year":"1986","journal-title":"Neuroscience Letters"},{"issue":"8","key":"10.1016\/bs.irn.2023.06.002_bib104","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/mds.27740","article-title":"Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders","volume":"34","author":"Moehle","year":"2019","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"6","key":"10.1016\/bs.irn.2023.06.002_bib105","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41386-020-00916-0","article-title":"The M1\/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain","volume":"46","author":"Montani","year":"2021","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2023.06.002_bib106","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-3-030-61663-2_2","article-title":"Synthetic and natural derivatives of cannabidiol","volume":"1297","author":"Morales","year":"2021","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"14","key":"10.1016\/bs.irn.2023.06.002_bib107","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1080\/14656566.2020.1787379","article-title":"An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease","volume":"21","author":"Muller","year":"2020","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"8","key":"10.1016\/bs.irn.2023.06.002_bib108","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/brain\/awaa178","article-title":"Early-infantile onset epilepsy and developmental delay caused by bi-allelic GAD1 variants","volume":"143","author":"Neuray","year":"2020","journal-title":"Brain"},{"issue":"594","key":"10.1016\/bs.irn.2023.06.002_bib109","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1564","article-title":"Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism","volume":"13","author":"Ng","year":"2021","journal-title":"Science Translational Medicine"},{"issue":"10","key":"10.1016\/bs.irn.2023.06.002_bib110","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nrneurol.2015.172","article-title":"Monoamine neurotransmitter disorders\u2014Clinical advances and future perspectives","volume":"11","author":"Ng","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/bs.irn.2023.06.002_bib111","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neulet.2017.09.014","article-title":"Resting state fMRI observations of baseline brain functional activities and connectivities in primary blepharospasm","volume":"660","author":"Ni","year":"2017","journal-title":"Neuroscience Letters"},{"key":"10.1016\/bs.irn.2023.06.002_bib112","unstructured":"NICE. (2017). Parkinson\u2019s disease in adults."},{"key":"10.1016\/bs.irn.2023.06.002_bib113","unstructured":"NIH. (2022). RePORT: Estimates of funding for various research, condition, and disease categories (RCDC). From \u3008https:\/\/report.nih.gov\/funding\/categorical-spending#\/\u3009."},{"key":"10.1016\/bs.irn.2023.06.002_bib114","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","article-title":"Metabotropic glutamate receptors: physiology, pharmacology, and disease","volume":"50","author":"Niswender","year":"2010","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"2","key":"10.1016\/bs.irn.2023.06.002_bib115","first-page":"S7","article-title":"GABAA receptors: Subtypes, regional distribution, and function","volume":"2","author":"Nutt","year":"2006","journal-title":"Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine"},{"key":"10.1016\/bs.irn.2023.06.002_bib116","unstructured":"Obstoj-Cardwell, B. (2022). Addex Phase IIa study of dipraglurant in blepharospasm misses goal. The Pharma Letter. Retrieved 08\/07\/2022, from \u3008https:\/\/www.thepharmaletter.com\/article\/addex-phase-iia-study-of-dipraglurant-in-blepharospasm-misses-goal\u3009."},{"issue":"6","key":"10.1016\/bs.irn.2023.06.002_bib117","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/epi.12987","article-title":"GRIN1 mutations cause encephalopathy with infantile-onset epilepsy, and hyperkinetic and stereotyped movement disorders","volume":"56","author":"Ohba","year":"2015","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/bs.irn.2023.06.002_bib118","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1474-4422(19)30396-5","article-title":"Apomorphine sublingual film for off episodes in Parkinson's disease: A randomised, double-blind, placebo-controlled phase 3 study","volume":"19","author":"Olanow","year":"2020","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2023.06.002_bib119","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","article-title":"Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: A randomised, controlled, double-blind, double-dummy study","volume":"13","author":"Olanow","year":"2014","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2023.06.002_bib120","doi-asserted-by":"crossref","first-page":"fcab078","DOI":"10.1093\/braincomms\/fcab078","article-title":"Dopaminergic restoration of prefrontal cortico-putaminal network in gene therapy for aromatic l-amino acid decarboxylase deficiency","volume":"3","author":"Onuki","year":"2021","journal-title":"Brain Communications"},{"issue":"1","key":"10.1016\/bs.irn.2023.06.002_bib121","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1055\/s-0043-1764140","article-title":"Global Epidemiology of Movement Disorders: Rare or Underdiagnosed?","volume":"43","author":"O\u2019Shea","year":"2023","journal-title":"Semin Neurol"},{"issue":"12","key":"10.1016\/bs.irn.2023.06.002_bib122","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1474-4422(21)00356-2","article-title":"Amantadine: An old drug reborn","volume":"20","author":"Pahwa","year":"2021","journal-title":"Lancet Neurology"},{"issue":"9923","key":"10.1016\/bs.irn.2023.06.002_bib123","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","article-title":"Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson\u2019s disease: a dose escalation, open-label, phase 1\/2 trial","volume":"383","author":"Palfi","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/bs.irn.2023.06.002_bib124","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/ncomms2144","article-title":"Opposing regulation of dopaminergic activity and exploratory motor behavior by forebrain and brainstem cholinergic circuits","volume":"3","author":"Patel","year":"2012","journal-title":"Nature Communications"},{"issue":"5","key":"10.1016\/bs.irn.2023.06.002_bib125","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/jimd.12247","article-title":"AADC deficiency from infancy to adulthood: Symptoms and developmental outcome in an international cohort of 63 patients","volume":"43","author":"Pearson","year":"2020","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"1","key":"10.1016\/bs.irn.2023.06.002_bib126","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1038\/s41467-021-24524-8","article-title":"Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons","volume":"12","author":"Pearson","year":"2021","journal-title":"Nature Communications"},{"key":"10.1016\/bs.irn.2023.06.002_bib127","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.neubiorev.2021.01.024","article-title":"The postnatal GABA shift: A developmental perspective","volume":"124","author":"Peerboom","year":"2021","journal-title":"Neuroscience and Biobehavioral Reviews"},{"issue":"8","key":"10.1016\/bs.irn.2023.06.002_bib128","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00702-018-1869-1","article-title":"Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia","volume":"125","author":"Perez-Lloret","year":"2018","journal-title":"Journal of Neural Transmission (Vienna)"},{"issue":"6","key":"10.1016\/bs.irn.2023.06.002_bib129","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/00006565-199912000-00018","article-title":"Chloral hydrate: The good and the bad","volume":"15","author":"Pershad","year":"1999","journal-title":"Pediatric Emergency Care"},{"issue":"7","key":"10.1016\/bs.irn.2023.06.002_bib130","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/jmedgenet-2016-104509","article-title":"GRIN2B encephalopathy: Novel findings on phenotype, variant clustering, functional consequences and treatment aspects","volume":"54","author":"Platzer","year":"2017","journal-title":"Journal of Medical Genetics"},{"key":"10.1016\/bs.irn.2023.06.002_bib131","series-title":"GeneReviews\u00ae [Internet].","first-page":"1993","article-title":"GRIN2D-related developmental and epileptic encephalopathy","author":"Platzer","year":"2022"},{"issue":"8","key":"10.1016\/bs.irn.2023.06.002_bib132","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/mds.25382","article-title":"Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency","volume":"28","author":"Pons","year":"2013","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"20","key":"10.1016\/bs.irn.2023.06.002_bib133","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","article-title":"Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: A report of the AAN Guideline Subcommittee","volume":"97","author":"Pringsheim","year":"2021","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/bs.irn.2023.06.002_bib134","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","article-title":"Amantadine in the treatment of Parkinson's disease and other movement disorders","volume":"20","author":"Rascol","year":"2021","journal-title":"Lancet Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2023.06.002_bib135","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4103\/0976-3147.169804","article-title":"Sertraline induced acute mandibular dystonia","volume":"6","author":"Raveendranathan","year":"2015","journal-title":"Journal of Neurosciences in Rural Practice"},{"issue":"2","key":"10.1016\/bs.irn.2023.06.002_bib136","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41380-021-01341-5","article-title":"The dopamine transporter gene SLC6A3: Multidisease risks","volume":"27","author":"Reith","year":"2022","journal-title":"Molecular Psychiatry"},{"issue":"1","key":"10.1016\/bs.irn.2023.06.002_bib137","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: The next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nature Reviews Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2023.06.002_bib138","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0014-2999(95)00878-0","article-title":"Antidystonic effects of L-type Ca2+ channel antagonists in a hamster model of idiopathic dystonia","volume":"300","author":"Richter","year":"1996","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"10.1016\/bs.irn.2023.06.002_bib139","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/brain\/awab123","article-title":"Aromatic l-amino acid decarboxylase deficiency: A patient-derived neuronal model for precision therapies","volume":"144","author":"Rossignoli","year":"2021","journal-title":"Brain"},{"issue":"8","key":"10.1016\/bs.irn.2023.06.002_bib140","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochemical Research"},{"issue":"2","key":"10.1016\/bs.irn.2023.06.002_bib141","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3233\/JHD-170283","article-title":"Cannabinoids for treatment of dystonia in Huntington's disease","volume":"7","author":"Saft","year":"2018","journal-title":"Journal of Huntington's Disease"},{"issue":"1-3","key":"10.1016\/bs.irn.2023.06.002_bib142","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejphar.2007.01.067","article-title":"Effects of intrastriatal injections of glutamate receptor antagonists on the severity of paroxysmal dystonia in the dtsz mutant","volume":"593","author":"Sander","year":"2007","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/bs.irn.2023.06.002_bib143","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1038\/s41467-019-10910-w","article-title":"AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders","volume":"10","author":"Salpietro","year":"2019","journal-title":"Nature Communications"},{"key":"10.1016\/bs.irn.2023.06.002_bib144","doi-asserted-by":"crossref","first-page":"14049","DOI":"10.1038\/mtm.2014.49","article-title":"Safety and tolerability of MRI-guided infusion of AAV2-hAADC into the mid-brain of non-human primate","volume":"3","author":"San Sebastian","year":"2014","journal-title":"Molecular Therapy\u2014Methods & Clinical Development"},{"key":"10.1016\/bs.irn.2023.06.002_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105650","article-title":"Striatal synaptic dysfunction in dystonia and levodopa-induced dyskinesia","volume":"166","author":"Scarduzio","year":"2022","journal-title":"Neurobiology of Disease"},{"issue":"1","key":"10.1016\/bs.irn.2023.06.002_bib146","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/glia.22389","article-title":"The quad-partite synapse: Microglia-synapse interactions in the developing and mature CNS","volume":"61","author":"Schafer","year":"2013","journal-title":"Glia"},{"issue":"5","key":"10.1016\/bs.irn.2023.06.002_bib147","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.pneurobio.2007.05.001","article-title":"Adenosine A2A receptors and basal ganglia physiology","volume":"83","author":"Schiffmann","year":"2007","journal-title":"Progress in Neurobiology"},{"key":"10.1016\/bs.irn.2023.06.002_bib148","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/164_2019_298","article-title":"Molecular mechanism and cannabinoid pharmacology","volume":"258","author":"Schurman","year":"2020","journal-title":"Handbook of Experimental Pharmacology"},{"issue":"21","key":"10.1016\/bs.irn.2023.06.002_bib149","doi-asserted-by":"crossref","first-page":"R1051","DOI":"10.1016\/j.cub.2015.09.039","article-title":"Organization of the locus coeruleus-norepinephrine system","volume":"25","author":"Schwarz","year":"2015","journal-title":"Current Biology: CB"},{"issue":"3","key":"10.1016\/bs.irn.2023.06.002_bib150","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.nbd.2012.04.015","article-title":"Cholinergic dysregulation produced by selective inactivation of the dystonia-associated protein torsinA","volume":"47","author":"Sciamanna","year":"2012","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/bs.irn.2023.06.002_bib151","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.neuropharm.2014.06.013","article-title":"Negative allosteric modulation of mGlu5 receptor rescues striatal D2 dopamine receptor dysfunction in rodent models of DYT1 dystonia","volume":"85","author":"Sciamanna","year":"2014","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/bs.irn.2023.06.002_bib152","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024261","article-title":"Developmental profile of the aberrant dopamine D2 receptor response in striatal cholinergic interneurons in DYT1 dystonia","volume":"6","author":"Sciamanna","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/bs.irn.2023.06.002_bib153","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1089\/humc.2017.010","article-title":"Persistent expression of dopamine-synthesizing enzymes 15 years after gene transfer in a primate model of Parkinson's disease","volume":"28","author":"Sehara","year":"2017","journal-title":"Human Gene Therapy Clinical Development"},{"key":"10.1016\/bs.irn.2023.06.002_bib154","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1126\/sciadv.abg3362","article-title":"Molecular mechanisms of metabotropic GABA(B) receptor function","volume":"7","author":"Shaye","year":"2021","journal-title":"Science Advances"},{"key":"10.1016\/bs.irn.2023.06.002_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.05.001","article-title":"\u201cDystonia and Parkinson\u2019s disease: What is the relationship?\u201d","volume":"132","author":"Shetty","year":"2019","journal-title":"Neurobiology of Disease"},{"issue":"3","key":"10.1016\/bs.irn.2023.06.002_bib156","doi-asserted-by":"crossref","first-page":"238","DOI":"10.14802\/jmd.20014","article-title":"Recurrent ADCY5 mutation in mosaic form with nocturnal paroxysmal dyskinesias and video electroencephalography documentation of dramatic response to caffeine treatment","volume":"13","author":"Shetty","year":"2020","journal-title":"Journal of Movement Disorders"},{"issue":"19","key":"10.1016\/bs.irn.2023.06.002_bib157","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1523\/JNEUROSCI.17-19-07503.1997","article-title":"Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus","volume":"17","author":"Shigemoto","year":"1997","journal-title":"The Journal of Neuroscience"},{"issue":"5","key":"10.1016\/bs.irn.2023.06.002_bib158","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0197-0186(99)00045-5","article-title":"Structure and subunit composition of GABA(A) receptors","volume":"34","author":"Sieghart","year":"1999","journal-title":"Neurochemistry International"},{"issue":"2","key":"10.1016\/bs.irn.2023.06.002_bib159","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/17512433.2020.1724535","article-title":"Inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson's disease","volume":"13","author":"Simoes","year":"2020","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10.1016\/bs.irn.2023.06.002_bib160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-540-74805-2_1","article-title":"Neurotransmitter release","volume":"184","author":"Suudhof","year":"2008","journal-title":"Handbook of Experimental Pharmacology"},{"issue":"2","key":"10.1016\/bs.irn.2023.06.002_bib161","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ymthe.2021.11.005","article-title":"Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency","volume":"30","author":"Tai","year":"2022","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.irn.2023.06.002_bib162","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/molecules26216530","article-title":"RNA activation\u2014A novel approach to therapeutically upregulate gene transcription","volume":"26","author":"Tan","year":"2021","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"6","key":"10.1016\/bs.irn.2023.06.002_bib163","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/ana.410070611","article-title":"Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations","volume":"7","author":"Thal","year":"1980","journal-title":"Annals of Neurology"},{"issue":"9","key":"10.1016\/bs.irn.2023.06.002_bib164","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/mds.26659","article-title":"A phase 2A trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson\u2019s disease","volume":"31","author":"Tison","year":"2016","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"7","key":"10.1016\/bs.irn.2023.06.002_bib165","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1111\/ejn.14742","article-title":"What\u2019s wrong with the striatal cholinergic interneurons in Parkinson's disease? Focus on intrinsic excitability","volume":"53","author":"Tubert","year":"2021","journal-title":"The European Journal of Neuroscience"},{"key":"10.1016\/bs.irn.2023.06.002_bib166","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1113\/jphysiol.1990.sp017989","article-title":"Muscarine reduces inwardly rectifying potassium conductance in rat nucleus accumbens neurones","volume":"422","author":"Uchimura","year":"1990","journal-title":"The Journal of Physiology"},{"issue":"2","key":"10.1016\/bs.irn.2023.06.002_bib167","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM197701132960203","article-title":"Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa","volume":"296","author":"Van Woert","year":"1977","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2023.06.002_bib168","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/bs.irn.2019.06.013","article-title":"Dysfunction of serotonergic neurons in Parkinson's disease and dyskinesia","volume":"146","author":"Vegas-Suarez","year":"2019","journal-title":"International Review of Neurobiology"},{"issue":"Suppl 1","key":"10.1016\/bs.irn.2023.06.002_bib169","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.33549\/physiolres.932678","article-title":"Structure, function, and pharmacology of NMDA receptor channels","volume":"63","author":"Vyklicky","year":"2014","journal-title":"Physiological Research"},{"issue":"3","key":"10.1016\/bs.irn.2023.06.002_bib170","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10565-019-09475-7","article-title":"Off-target genome editing: A new discipline of gene science and a new class of medicine","volume":"35","author":"Wang","year":"2019","journal-title":"Cell Biology and Toxicology"},{"issue":"1","key":"10.1016\/bs.irn.2023.06.002_bib171","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13023-016-0522-z","article-title":"Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency","volume":"12","author":"Wassenberg","year":"2017","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"1","key":"10.1016\/bs.irn.2023.06.002_bib172","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-021-00314-w","article-title":"Essential tremor","volume":"7","author":"Welton","year":"2021","journal-title":"Nature Reviews Disease Primers"},{"issue":"7","key":"10.1016\/bs.irn.2023.06.002_bib173","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nrneurol.2015.86","article-title":"Dopa-responsive dystonia--clinical and genetic heterogeneity","volume":"11","author":"Wijemanne","year":"2015","journal-title":"Nature Reviews Neurology"},{"issue":"46","key":"10.1016\/bs.irn.2023.06.002_bib174","doi-asserted-by":"crossref","first-page":"18163","DOI":"10.1073\/pnas.0708699104","article-title":"Mutations in ionotropic AMPA receptor 3 alter channel properties and are associated with moderate cognitive impairment in humans","volume":"104","author":"Wu","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.irn.2023.06.002_bib175","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418776932","article-title":"Antisense oligonucleotides in neurological disorders","volume":"11","author":"Wurster","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"issue":"10","key":"10.1016\/bs.irn.2023.06.002_bib176","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s13238-022-00912-8","article-title":"New pathogenic insights from large animal models of neurodegenerative diseases","volume":"13","author":"Yin","year":"2022","journal-title":"Protein Cell"},{"issue":"1","key":"10.1016\/bs.irn.2023.06.002_bib177","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13041-017-0306-y","article-title":"The role of 5-HT receptors in depression","volume":"10","author":"Yohn","year":"2017","journal-title":"Molecular Brain"},{"key":"10.1016\/bs.irn.2023.06.002_bib178","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.neunet.2022.05.027","article-title":"Exploring phase-amplitude coupling from primary motor cortex-basal ganglia-thalamus network model","volume":"153","author":"Yu","year":"2022","journal-title":"Neural Networks: The Official Journal of the International Neural Network Society"},{"issue":"5","key":"10.1016\/bs.irn.2023.06.002_bib179","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00417-021-05533-1","article-title":"Medical cannabis oil for benign essential blepharospasm: A prospective, randomized controlled pilot study","volume":"260","author":"Zloto","year":"2022","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie"}],"container-title":["International Review of Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774223000508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774223000508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T14:55:53Z","timestamp":1708786553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774223000508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9780323990264"],"references-count":179,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2023.06.002","relation":{},"ISSN":["0074-7742"],"issn-type":[{"type":"print","value":"0074-7742"}],"subject":[],"published":{"date-parts":[[2023]]}}}